The Burden of Chemotherapy-Induced Myelosuppression in Patients with Small Cell Lung Cancer: What’s New?
Webinar Recorded on Oct. 1, 2020
Sponsored by G1 Therapeutics, Inc.
Chemotherapy-induced myelosuppression (CIM) is one of the most common dose-limiting complications of cancer treatment and is associated with a range of debilitating symptoms that significantly impact patients’ quality of life. Physical manifestations include neutropenia, anemia, and thrombocytopenia – all of which can cascade into severe complications. These undeniable risks of cancer therapy persist despite the availability of guideline directed protocols of care and a ready assortment of rescue treatment options. Currently, however, there is no available solution that mitigates the myelosuppressive effects of chemotherapy before they occur. Therein lies an unmet need.
Join Drs. Rob Epstein and Marc Chioda as they reframe the landscape of CIM with a fresh perspective on the root of the clinical problem, the patient burden revealed through real world management of CIM, and the hope for a future that fulfills the unmet need – one made more complicated by the confounding influence of Covid-19 in the day-to-day management of people facing malignancy. Better communication between people and their health care teams could help them to understand how people experience myelosuppression and make plans for treatment together.
- Chemotherapy-induced myelosuppression (CIM) in 2020 and beyond
- Current available therapies and clinical recommendations for managing CIM
- Health economic and patient reported experience that redefine the real-world impact of CIM
- Investigational therapies that focus on the root of the problem
- Robert Epstein, MD
Epstein Health LLC.
- Marc Chioda, PharmD
VP, Medical Affairs
G1 Therapeutics, Inc.
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.